Charles Foussard

Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support

Nöel Milpied, Éric Deconinck, Fanny Gaillard et al. · New England Journal of Medicine · 2004 · 341 citations · Full text

Medicine, Hematology, Oncology +13

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

Gilles Salles, Nicolas Mounier, Sophie de Guibert et al. · Blood · 2008 · 331 citations

Medicine, Hematology, Oncology +11

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

Danielle Canioni, Gilles Salles, Nicolas Mounier et al. · Journal of Clinical Oncology · 2007 · 245 citations

Medicine, Immunology, Oncology +17

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

Audrey Simon, Michel Péoc’h, Philippe Casassus et al. · British Journal of Haematology · 2010 · 165 citations · Full text

Medicine, Hematology, Oncology +12

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13